Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial

Lancet

Volumn 357, Issue 9253, 2001, Pages 336-341

  Tu, Shi Ming ^a   Millikan, Randall E ^a   Mengistu, Bayabel ^a   Delpassand, Ebrahim S ^a   Amato, Robert J ^a   Pagliaro, Lance C ^a   Daliani, Danai ^a   Papandreou, Christos N ^a   Smith, Terry L ^a   Kim, Jeri ^a   Podoloff, Donald A ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE; HYDROCORTISONE; KETOCONAZOLE; STRONTIUM 89; VINBLASTINE;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035798930     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03639-4     Document Type: Article

References (30)

1. The anatomy and pathways of skeletal metastases
2. Carcinoma of the prostate: Metastases, therapy, and survival - A statistical analysis of 500 cases
3. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
4. Mechanisms of the development of osteoblastic metastasis
5. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
6. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
7. Nuclear bone imaging in metastatic cancer of the prostate
8. Orchiectomy versus goserelin and fiutamide in the treatment of newly diagnosed metastatic prostate cancer: Analysis of the criteria of evaluation used in the European Organisation for Research and Treatment of Cancer - Gentourinary Group Study 30853
9. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
10. Treatment of liver metastases
11. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: Analysis of prognostic factors
12. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone
13. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
14. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
15. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer
16. Randomized phase II clinical trials
17. Prognostic factors for survival in patients with inoperable lung cancer
18. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
19. Nonparametric estimation from incomplete observation
20. Evaluation of survival data and two new rank order statistics arising in its consideration
21. Toxicity and response criteria of the Eastern Cooperative Oncology Group
22. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer
23. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
24. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
25. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer
26. False-positive results in clinical trials: Multiple significance tests and the problem of unreported comparisons
27. False positive rates of randomized phase II designs
28. The function of the vertebral veins and their role in the spread of metastasis
29. The distribution of growths in cancer of the breast
30. Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma